Today, I’m initiating coverage on Intellia Therapeutics (NTLA).
After reviewing the daily, weekly, monthly, and quarterly charts, I believe NTLA offers an attractive long-term risk/reward profile at current levels.
In this video, I discuss:
• Technical setup
• Gene editing opportunity
• 2026–2027 catalysts
• Risks and rewards
• Why I’m initiating coverage
Here’s what I’m seeing. Think for yourself.
Disclosure: Long shares of NTLA.
